PLXProtalix BioTherapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $2.68 · now $2.68 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, PLX has typically landed between $2.12 and $3.63 — a range of −21.0% to +35.6% from the issuance price $2.68.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,999 overlapping 1 month windows · 2006-09-262026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.68) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where PLX has typically landed a month from the 2026-09-16 close of $2.68 — the range is history, not a prediction.

$2.12worst · -21.0%$3.63best · +35.6%
  • now $2.68 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.69 (+0.4%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.4$2.98
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.12$3.63
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,999 windows spanning 2006-09-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2007-10-24−88.9%−88.9%+0.0%
2007-10-22−88.2%−88.2%+0.0%
2007-10-23−88.0%−88.0%+0.8%
3 best
2017-01-12+223.5%+0.0%+223.5%
2017-01-13+190.7%+0.0%+204.7%
2017-01-17+171.7%+0.0%+184.8%

4,999 overlapping windows · 2006-09-262026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
75%
+13.5%
n=20
Feb
40%
+3.8%
n=20
Mar
35%
+0.0%
n=20
Apr
55%
+5.3%
n=20
May
20%
−4.9%
n=20
Jun
45%
−2.8%
n=20
Jul
40%
−4.3%
n=20
Aug
40%
−0.7%
n=20
Sep
45%
+5.1%
n=20
Oct
40%
−5.7%
n=20
Nov
35%
−1.2%
n=20
Dec
40%
−3.0%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$12025-12-19: 1 insider purchase, $101K — Bashan Dror2025-11-18: 1 insider sale, $314 — Bar-Shalev Amos2025-11: 1 open-market sale, $3142025-12: 1 open-market purchase, $101K↑ buys↓ salesdirector Bashan Dror — Purchase on 2025-12-19, filed 4 days after the tradedirector Bar-Shalev Amos — Sale on 2025-11-18, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-12-19Bashan DrordirectorPurchase56,000 @ $1.81$101K+42.3% of holding+19.6%+21.2%188,516Form 4 · filed 4 days after the trade
2025-11-18Bar-Shalev AmosdirectorSale168 @ $1.87$314−100.0% of holding−6.7%−5.2%0Form 4 · filed 1 day after the trade
2025-06-10Schwartz AharondirectorPurchase129,000 @ $1.60$206K+74.1% of holding−14.5%−3.1%303,000Form 4 · filed 63 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

45 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-09-03Bashan DrordirectorAward / grant160,000160,000Form 4
2026-09-03Bar-Shalev AmosdirectorAward / grant17,00017,000Form 4
2026-09-03Schwartz AharondirectorAward / grant8,5008,500Form 4
2026-09-03Schwartz AharondirectorAward / grant17,00017,000Form 4
2026-09-03Bar-Shalev AmosdirectorAward / grant8,5008,500Form 4
2026-09-03Bashan DrordirectorAward / grant320,000320,000Form 4
2026-09-03Ben Zvi ShmueldirectorAward / grant8,5008,500Form 4
2026-09-03Ben Zvi ShmueldirectorAward / grant17,00017,000Form 4
2026-09-03Boudes Pol FdirectorAward / grant17,00017,000Form 4
2026-09-03Boudes Pol FdirectorAward / grant8,5008,500Form 4
2026-09-03Elze ChristiandirectorAward / grant17,00017,000Form 4
2026-09-03Elze ChristiandirectorAward / grant8,5008,500Form 4
2026-09-03Forster EliotdirectorAward / grant17,00017,000Form 4
2026-09-03Forster EliotdirectorAward / grant8,5008,500Form 4
2026-09-03Melincoff Gwen AdirectorAward / grant17,00017,000Form 4
2026-09-03Melincoff Gwen AdirectorAward / grant8,5008,500Form 4
2026-09-03Naos YaronofficerAward / grant112,000112,000Form 4
2026-09-03Naos YaronofficerAward / grant56,00056,000Form 4
2025-09-03Bar-Shalev AmosdirectorAward / grant15,00015,000Form 4
2025-09-03Naos YaronofficerAward / grant50,00050,000Form 4
2025-09-03Schwartz AharondirectorAward / grant15,00015,000Form 4
2025-09-03Melincoff Gwen AdirectorAward / grant15,00015,000Form 4
2025-09-03Bashan DrordirectorAward / grant340,000340,000Form 4
2025-09-03Ben Zvi ShmueldirectorAward / grant15,00015,000Form 4
2025-09-03Boudes Pol FdirectorAward / grant15,00015,000Form 4
2025-09-03Elze ChristiandirectorAward / grant15,00015,000Form 4
2025-09-03Forster EliotdirectorAward / grant15,00015,000Form 4
2025-09-03Elze ChristiandirectorAward / grant7,5007,500Form 4
2025-09-03Schwartz AharondirectorAward / grant7,5007,500Form 4
2025-09-03Boudes Pol FdirectorAward / grant7,5007,500Form 4
2025-09-03Forster EliotdirectorAward / grant7,5007,500Form 4
2025-09-03Elze ChristiandirectorAward / grant7,5007,500Form 4
2025-09-03Naos YaronofficerAward / grant25,000225,817Form 4
2025-09-03Forster EliotdirectorAward / grant7,5007,500Form 4
2025-09-03Bar-Shalev AmosdirectorAward / grant7,5007,500Form 4
2025-09-03Bar-Shalev AmosdirectorAward / grant7,5007,500Form 4
2025-09-03Ben Zvi ShmueldirectorAward / grant7,5007,500Form 4
2025-09-03Melincoff Gwen AdirectorAward / grant7,5007,500Form 4
2025-09-03Bashan DrordirectorAward / grant195,0002,344,418Form 4
2025-09-03Naos YaronofficerAward / grant25,000225,817Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.